These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23289899)

  • 1. NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study.
    Wigal SB; Childress AC; Belden HW; Berry SA
    J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):3-10. PubMed ID: 23289899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.
    Wigal SB; Childress A; Berry SA; Belden H; Walters F; Chappell P; Sherman N; Orazem J; Palumbo D
    J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):690-699. PubMed ID: 28557548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting.
    Childress AC; Kollins SH; Cutler AJ; Marraffino A; Sikes CR
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):66-74. PubMed ID: 27183299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Multilayer, Extended-Release Methylphenidate (PRC-063) in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder: A Laboratory Classroom Study.
    Childress AC; Brams MN; Cutler AJ; Donnelly GAE; Bhaskar S
    J Child Adolesc Psychopharmacol; 2020 Dec; 30(10):580-589. PubMed ID: 33090921
    [No Abstract]   [Full Text] [Related]  

  • 5. Early-Onset Efficacy and Safety Pilot Study of Amphetamine Extended-Release Oral Suspension in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder.
    Childress AC; Kando JC; King TR; Pardo A; Herman BK
    J Child Adolesc Psychopharmacol; 2019 Feb; 29(1):2-8. PubMed ID: 30575407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized placebo-controlled double-blind study evaluating the time course of response to methylphenidate hydrochloride extended-release capsules in children with attention-deficit/hyperactivity disorder.
    Wigal SB; Greenhill LL; Nordbrock E; Connor DF; Kollins SH; Adjei A; Childress A; Stehli A; Kupper RJ
    J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):562-9. PubMed ID: 25470572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study.
    Childress AC; Brams M; Cutler AJ; Kollins SH; Northcutt J; Padilla A; Turnbow JM
    J Child Adolesc Psychopharmacol; 2015 Jun; 25(5):402-14. PubMed ID: 25692608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings.
    Childress AC; Cutler AJ; Marraffino A; McDonnell MA; Turnbow JM; Brams M; DeSousa NJ; Incledon B; Sallee FR; Wigal SB
    J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):2-14. PubMed ID: 31464511
    [No Abstract]   [Full Text] [Related]  

  • 9. A Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder.
    Kollins SH; Braeckman R; Guenther S; Barrett AC; Mickle TC; Oh C; Marraffino A; Cutler AJ; Brams MN
    J Child Adolesc Psychopharmacol; 2021 Nov; 31(9):597-609. PubMed ID: 34714120
    [No Abstract]   [Full Text] [Related]  

  • 10. A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect.
    Brams M; Muniz R; Childress A; Giblin J; Mao A; Turnbow J; Borrello M; McCague K; Lopez FA; Silva R
    CNS Drugs; 2008; 22(8):693-704. PubMed ID: 18601306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder.
    Wigal SB; Wigal T; Schuck S; Brams M; Williamson D; Armstrong RB; Starr HL
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):121-31. PubMed ID: 21488750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder.
    Childress AC; Wigal SB; Brams MN; Turnbow JM; Pincus Y; Belden HW; Berry SA
    J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):306-313. PubMed ID: 29211967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, Safety, and Tolerability of a Novel Methylphenidate Extended-Release Oral Suspension (MEROS) in ADHD.
    Robb AS; Findling RL; Childress AC; Berry SA; Belden HW; Wigal SB
    J Atten Disord; 2017 Dec; 21(14):1180-1191. PubMed ID: 24874348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder.
    Silva RR; Muniz R; Pestreich L; Childress A; Brams M; Lopez FA; Wang J
    J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):239-51. PubMed ID: 16768632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of children with attention-deficit/hyperactivity disorder: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and D,L-methylphenidate and placebo in a laboratory classroom setting.
    Silva R; Muniz R; McCague K; Childress A; Brams M; Mao A
    Psychopharmacol Bull; 2008; 41(1):19-33. PubMed ID: 18362868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day.
    Faraone SV; Childress AC; Gomeni R; Rafla E; Kando JC; Dansie L; Naik P; Pardo A
    J Child Adolesc Psychopharmacol; 2023 Feb; 33(1):14-19. PubMed ID: 36730749
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study.
    Muniz R; Brams M; Mao A; McCague K; Pestreich L; Silva R
    J Child Adolesc Psychopharmacol; 2008 Jun; 18(3):248-56. PubMed ID: 18582179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-release dexmethylphenidate 30 mg/d versus 20 mg/d: duration of attention, behavior, and performance benefits in children with attention-deficit/hyperactivity disorder.
    Silva RR; Brams M; McCague K; Pestreich L; Muniz R
    Clin Neuropharmacol; 2013; 36(4):117-21. PubMed ID: 23860345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension.
    Childress AC; Berry SA
    Postgrad Med; 2010 Sep; 122(5):35-41. PubMed ID: 20861586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.